Menu
Search
|

Menu

Close
X

Savara Inc SVRA.OQ (NASDAQ Stock Exchange Global Select Market)

9.39 USD
-0.12 (-1.26%)
As of Nov 16
chart
Previous Close 9.51
Open 9.40
Volume 58,151
3m Avg Volume 55,173
Today’s High 9.63
Today’s Low 9.26
52 Week High 17.11
52 Week Low 8.48
Shares Outstanding (mil) 24.20
Market Capitalization (mil) 229.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.630
FY17
-3.157
FY16
-6.540
FY15
-17.192
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
1,794.46
5.69
Price to Book (MRQ)
vs sector
2.88
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
19.55
15.71
LT Debt to Equity (MRQ)
vs sector
18.65
11.53
Return on Investment (TTM)
vs sector
-43.82
15.05
Return on Equity (TTM)
vs sector
-65.80
16.62

EXECUTIVE LEADERSHIP

Robert Neville
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Taneli Jouhikainen
President, Chief Operating Officer, Since 2017
Salary: --
Bonus: --
David Lowrance
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Nevan Elam
Independent Director, Since 2017
Salary: --
Bonus: --
Richard Hawkins
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

900 S Capital of Texas Hwy Ste 1
WEST LAKE HILLS   TX   78746-5436

Phone: +1512.6141848

Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.

SPONSORED STORIES